User profiles for OSCAR ARRIETA

Oscar Arrieta

Head of the Thoracic Oncology Unit, Instituto Nacional de Cancerología de Mexico
Verified email at unam.mx
Cited by 26808

[HTML][HTML] Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer

…, F Barlesi, M Kohlhäufl, O Arrieta… - … England Journal of …, 2015 - Mass Medical Soc
Background Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint–inhibitor
antibody, disrupts PD-1–mediated signaling and may restore antitumor immunity. …

[HTML][HTML] Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with …

O Arrieta, RM Michel Ortega, G Villanueva-Rodríguez… - BMC cancer, 2010 - Springer
Background A frequent manifestation of advanced NSCLC is malnutrition, even though
there are many studies which relate it with a poor survival, its relation with toxicity has not yet …

Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer

Ó Arrieta, LP Angulo, C Núñez-Valencia… - Annals of surgical …, 2013 - Springer
Background Symptoms of depression and anxiety are common in patients with lung cancer
and may produce an impact on both health-related quality of life (HRQL) and survival. The …

[HTML][HTML] The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis

O Arrieta, B Cacho, D Morales-Espinosa… - BMC cancer, 2007 - Springer
Background Hepatocellular carcinoma is the most common cause of primary liver
neoplasms and is one of the main causes of death in patients with liver cirrhosis. High Alpha …

Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor–mutated lung …

O Arrieta, F Barrón, MÁS Padilla, A Avilés-Salas… - JAMA …, 2019 - jamanetwork.com
Importance Metformin hydrochloride is emerging as a repurposed anticancer drug. Preclinical
and retrospective studies have shown that it improves outcomes across a wide variety of …

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum …

EB Garon, TE Ciuleanu, O Arrieta, K Prabhash… - The Lancet, 2014 - thelancet.com
Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular
domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel …

[HTML][HTML] Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label …

…, F Barlesi, S Antonia, O Arrieta… - Journal of clinical …, 2017 - ncbi.nlm.nih.gov
… Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlesi, Scott Antonia, Oscar
Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer Rizvi, Martin Reck, Matthew D. Hellmann …

[HTML][HTML] Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung …

…, A Pluzanski, O Arrieta… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Immunotherapy has revolutionized the treatment of advanced non–small-cell lung
cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab …

Triple‐negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity

…, E Bargalló, JL Aguilar, A Mohar, Ó Arrieta - Cancer, 2011 - Wiley Online Library
BACKGROUND: Triple‐negative breast cancer (TNBC) is defined as breast cancer that is
negative for estrogen receptor, progesterone receptor, and human epidermal growth factor …

[HTML][HTML] Radiation-induced lung injury: current evidence

…, W Muñoz-Montaño, M Nuñez-Baez, O Arrieta - BMC pulmonary …, 2021 - Springer
Chemo-radiotherapy and systemic therapies have proven satisfactory outcomes as standard
treatments for various thoracic malignancies; however, adverse pulmonary effects, like …